PUMA
13.3.2024 12:27:35 CET | Business Wire | Press release
Sports company PUMA reduced its greenhouse gas emissions by 24% in 2023 compared to 2022, despite a strong sales growth.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240313721861/en/
Sports company PUMA reduced its greenhouse gas emissions by 24% in 2023 compared to 2022, despite a strong sales growth. (Photo: Business Wire)
This was made possible by its core suppliers doubling their use of renewable energy in 2023 compared to the previous year, increasing the use of less carbon intensive materials in its products, the introduction of low carbon shipment tariffs by PUMA’s logistics partner Maersk, by using renewable electricity or purchasing renewable energy certificates at its own operations and by investing in electric vehicles in its car fleet. Compared with the 2017 baseline, this means an absolute greenhouse gas emission reduction of 29%.
“We are very proud of the progress we have achieved on our sustainability journey in 2023, particularly when it comes to the reduction of greenhouse gases,” said Anne-Laure Descours, Chief Sourcing Officer at PUMA. “We will not stop there, however, and continue to execute our FOREVER.BETTER. sustainability strategy and our 10FOR25 targets.”
With an 85% reduction of own emissions and a 65% reduction of supply chain emissions relative to sales, PUMA achieved its first science-based greenhouse gas reduction target in 2023, seven years ahead of the target year 2030. PUMA’s new climate goals, which were approved by the Science Based Targets Initiative (SBTi), aim to reduce PUMA’s emissions by what scientists say is necessary to keep global warming below 1.5 degrees. By 2030, PUMA aims to reduce its absolute Scope 1 and 2 GHG emissions by 90% from a 2017 baseline year. The SBTi has classified PUMA Scope 1 and 2 targets as in line with a 1.5-degree trajectory. By 2030, PUMA also commits to reduce absolute Scope 3 GHG emissions from its supply chain and logistics by 33% compared to 2017.
Apart from increasing its climate ambitions, PUMA also made progress with its other 10FOR25 sustainability targets, reaching two out of ten targets ahead of schedule.
PUMA met its Plastics and the Oceans target by eliminating plastic carrier bags from its owned and operated stores and through researching biodegradable plastic options. An important part of this target was PUMA’s successful RE:SUEDE experiment, where it turned an experimental version of its classic Suede sneaker into compost under controlled industrial conditions. A commercial version will be launched in April 2024.
It also achieved its Human Rights target by training more than 220,000 factory workers on women’s empowerment and completely mapping subcontractors and Tier 2 suppliers for human rights risks. In addition, PUMA employees donated over 57,000 of community engagement hours.
Other progress included scaling up the use of recycled materials in 2023, producing 8 out of 10 products with a significant part of recycled or certified materials. Starting 2024, all* of PUMA’s replica football jerseys will be made using PUMA’s RE:FIBRE recycling technology which focuses on polyester textile waste as the primary source of material.
PUMA’s sustainability report is available at https://about.puma.com/en/sustainability/reporting
*excluding any locally sourced kits and replicas for Al Hilal, Galatasaray SK, Fenerbahce, Shakhtar Donetsk
PUMA
PUMA is one of the world’s leading sports brands, designing, developing, selling and marketing footwear, apparel and accessories. For more than 75 years, PUMA has relentlessly pushed sport and culture forward by creating fast products for the world’s fastest athletes. PUMA offers performance and sport-inspired lifestyle products in categories such as Football, Running and Training, Basketball, Golf, and Motorsports. It collaborates with renowned designers and brands to bring sport influences into street culture and fashion. The PUMA Group owns the brands PUMA, Cobra Golf and stitched. The company distributes its products in more than 120 countries, employs about 20,000 people worldwide, and is headquartered in Herzogenaurach/Germany.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240313721861/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
